Characteristics of HCs and patients with MPN with or without MF
| Characteristic . | HCs . | MPN without MF . | MPN with MF . |
|---|---|---|---|
| Patients | |||
| Total | 21 | 21 | 37 |
| Men | 5 | 8 | 19 |
| Women | 16 | 13 | 18 |
| Mean age (y) ± SD | 52.9 ± 9.0 | 62.6 ± 16.5 | 69.1 ± 12.1 |
| Genetic mutation | |||
| JAK2V617F | 9 | 19 | |
| CALR | 2 | 7 | |
| MPLW515L | 0 | 1 | |
| Primary disease | |||
| Polycythemia vera | 9 | 14 | |
| Essential thrombocythemia | 11 | 12 | |
| PMF | 0 | 11 | |
| Preprimary MF | 1 | 0 | |
| Medication | |||
| Hydroxyurea | 7 | 8 | |
| Anagrelide | 0 | 1 | |
| Ruxolitinib | 0 | 2 | |
| Interferon | 0 | 0 | |
| Splenomegaly | 0 | 16 |
| Characteristic . | HCs . | MPN without MF . | MPN with MF . |
|---|---|---|---|
| Patients | |||
| Total | 21 | 21 | 37 |
| Men | 5 | 8 | 19 |
| Women | 16 | 13 | 18 |
| Mean age (y) ± SD | 52.9 ± 9.0 | 62.6 ± 16.5 | 69.1 ± 12.1 |
| Genetic mutation | |||
| JAK2V617F | 9 | 19 | |
| CALR | 2 | 7 | |
| MPLW515L | 0 | 1 | |
| Primary disease | |||
| Polycythemia vera | 9 | 14 | |
| Essential thrombocythemia | 11 | 12 | |
| PMF | 0 | 11 | |
| Preprimary MF | 1 | 0 | |
| Medication | |||
| Hydroxyurea | 7 | 8 | |
| Anagrelide | 0 | 1 | |
| Ruxolitinib | 0 | 2 | |
| Interferon | 0 | 0 | |
| Splenomegaly | 0 | 16 |
CALR, calreticulin; JAK2, Janus-activating kinase 2; SD, standard deviation.